Protalix BioTherapeutics (PLX) Q2 FY26 earnings call

Protalix BioTherapeutics delivered strong Q2 FY26 results, primarily driven by the continued global expansion of Elfabrio through its partnership with Chiesi and a $25 million milestone payment recognized in Q1. The company reaffirmed its full-year revenue guidance, supported by a robust cash position, while advancing its PRX115 clinical program for uncontrolled gout with top-line Phase 2 results expected in H2 2027.